Newborn Screening Market
Newborn Screening Market - Global Industry Assessment & Forecast
Segments Covered
- By Product Consumables, Instruments, Hearing Screening Instruments, Pulse Oximeters
- By Test Dry Blood Spot Tests, Hearing Screening Test, CCHD Screening Test
- By Technology Immune Assays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry, Other Technologies
- By End User Clinical Laboratories, Hospitals
- By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base Year: | 2022 |
Forecast Years: | 2023 - 2030 |
Historical Years: | 2017 - 2021 |
Revenue 2022: | USD 785.86 Million |
Revenue 2030: | USD 1433.19 Million |
Revenue CAGR (2023 - 2030): | 7.80% |
Fastest Growing Region (2023 - 2030) | Asia Pacific |
Largest Region (2022): | North America |
Customization Offered
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
Research Methodology: Newborn Screening Market by Product by Test by Technology by End User by Region - Global Market Assessment, 2021 - 2028
Secondary Research
Primary Research:
The later stage covers data validation and collection from primary research. The information gained/procured from the secondary data sources is validated through extensive primary interviews with industry experts across the Newborn Screening supply chain. The primary research is also conducted to identify key players in the market and to gather and validate already procured information pertaining to their market-specific financial information. Moreover, primary research is used to gain/validate information about:
- Newborn Screening market size at regional and country level
- Key industry players and their market share and Newborn Screening market-specific sales/revenue
- Understanding of the Newborn Screening supply chain and overall ecosystem
Data Triangulation and Market Size Estimations
After arriving at the global market numbers, top-down and bottom-up approaches are used to estimate, validate and finalize the market size of the Newborn Screening market. After the determination of the overall market size, the market is divided into various segments and sub-segments. Moreover, these same approaches mentioned above were used to derive and estimate market numbers for mentioned segments/sub-segments in the market. During the data triangulation process, the data was analyzed by employing various data models and statistical techniques to arrive at exact statistics and market size for each segment/sub-segment of the market. The data is analyzed and triangulated by considering all the key market impacting factors from both supply and demand side of Newborn Screening market.
FAQ
Frequently Asked Question
What is the global demand for Newborn Screening in terms of revenue?
-
The global Newborn Screening valued at USD 785.86 Million in 2022 and is expected to reach USD 1433.19 Million in 2030 growing at a CAGR of 7.80%.
Which are the prominent players in the market?
-
The prominent players in the market are PerkinElmer (US), Demant A/S (Denmark), Natus Medical (US), Bio-Rad Laboratories (US), Danaher Corporation (US), Medtronic (Ireland), Chromsystems Instruments & Chemicals GmbH (Germany), Trivitron Healthcare (India), Baebies (US), Recipe Chemicals+Instruments (Germany).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 7.80% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Newborn Screening include
- Rising prevalence of newborn disorders
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Newborn Screening in 2022.